- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06251401
Cardiac Rehabilitation for Breast Cancer Survivors
Cardiac Rehabilitation for Breast Cancer Survivors at Risk for Cardiovascular Disease Secondary to Cardiotoxic Treatment
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rationale Our overarching goal is to support the development of innovative and scalable approaches to CVD prevention in early breast cancer (EBC) survivors. Cardiac rehabilitation (CR) is a cornerstone of both primary and secondary CVD risk management and may be similarly beneficial for survivors at risk of cancer-related CVD. However, it remains unknown if CR-based interventions can reduce CVD risk in those who have received cardiotoxic therapies. Further, the impact of exercise setting (i.e., in-person versus virtual) on intervention safety, adherence, and efficacy has also not been evaluated in this context. Lastly, whether psychosocial wellbeing affects program participation is also not well understood. Ultimately, our study will provide important pilot and feasibility data to inform future randomized trials in this area. It will also lay the foundation for a prospective cohort study that can evaluate the importance of biomarkers and clinical risk factors in predicting future CVD and will provide data that will help identify individuals who are most likely to benefit from aggressive CVD risk factor management.
Design The proposed study is a pragmatic randomized trial of in-person supervised versus virtually delivered CR in EBC survivors treated with anthracyclines and/or trastuzumab. The investigators will also study the evolution of cardiovascular risk markers in women with breast cancer after completion of potentially cardiotoxic chemotherapy.
Objectives and hypotheses
Our specific objectives and related hypotheses are:
- Primary objective: Assess the feasibility of conducting an adequately powered randomized trial of supervised versus virtual CR in older women (>50 years) with breast cancer who have been treated with anthracyclines and/or trastuzumab Hypothesis: The trial will demonstrate feasibility via the achievement of pre-determined thresholds for participant recruitment, retention, and intervention adherence to CR protocols.
Secondary objectives:
i. Derive estimates of intervention efficacy on markers of cardiac function and injury, aerobic fitness, non-trial physical activity behaviours (i.e., exercise behaviours beyond what is prescribed as part of CR), and psychosocial wellbeing (anxiety, depression, stress) Hypothesis: Improvements in imaging and serum biomarkers, aerobic fitness, and psychosocial measures will be comparable between the two intervention groups.
ii. Describe the prevalence of abnormal biomarkers from blood, cardiac imaging and stress testing with cardiovascular risk after breast cancer treatment Hypothesis: A substantial proportion of participants will have abnormal global longitudinal strain and serum biomarkers despite having normal LVEF. Estimated aerobic capacity will also be compromised when compared with age- and sex-norms.
Tertiary objectives:
i. Inform the development a novel pathway for cardiometabolic risk reduction for women with breast cancer at WCH, with these data being used to guide out-of-institution scalability Hypothesis: The investigators will identify potential barriers to referral and participation to inform the future development of this program pathway and will be able to determine any cancer-specific needs that may need to be addressed via the program.
ii. Quantify the differences in intervention delivery costs between the two study arms.
Hypothesis: Both in-person and virtual CR will be comparable in terms of utilization of consumable resources. Virtual rehabilitation will incur a greater healthcare professional (HCP) time cost for delivery when compared with in-person CR.
Intervention Briefly, in-person CR consists of once-weekly (or twice weekly if the participant is classified is being high risk, i.e., elevated blood pressure with exercise, or <85% age-predicted aerobic fitness) group-based supervised exercise training at WCH, supplemented with home-based exercise training, with the goal of reaching Canadian Physical Activity Guidelines of 150 minutes a week of moderate-intensity exercise per week. Exercise prescriptions are individualized at baseline by the CR team based on a symptom-limited stress test. Virtual CR consists of once-weekly telephone or video conferencing-based follow-ups (according to participant preference and access to internet/smart device) by one of the HCPs. Similar to the in-person program, the virtual program also encourages participants to set goals to achieve 150 minutes a week of moderate-intensity exercise. The exercise prescription is individualized to each participant's ability and can vary in number of sessions per week and duration of each exercise session, as per the HCP's discretion. Unlike the in-person program, all these sessions are completed at home in an unsupervised manner. Additionally, both study arms get have the opportunity to attend weekly synchronous virtual group video education sessions for the duration of the 12-week CR program with the focus on self-management education and support. The program's Registered Dietitian, Social Worker, and Pharmacist (who teach some of the education sessions) may offer 1:1 visits with the participants if necessary.
Statistical Analysis Participant demographics, clinical characteristics (including prevalence of abnormal biomarkers), and feasibility metrics (including reasons for non-participation) will be analyzed using descriptive statistics (mean ± standard deviation, and frequency (%), as applicable). Exercise and education session attendance will be reported as the proportion attended and compared between groups using the chi-square test (or Fisher's exact test, as appropriate). Exercise prescription adherence will be reported as the average percentage of exercise completed relative to exercise dose prescribed and will be compared between groups using independent-samples t-tests (or Wilcoxon Rank Sum test, as appropriate).
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Priya Brahmbhatt
- Phone Number: 416-323-6200
- Email: priya.brahmbhatt@wchospital.ca
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5S 1B3
- Recruiting
- Women's College Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- age > 50 years
- previous receipt of anthracyclines and/or trastuzumab for breast cancer
- ability to participate in in-person cardiac rehabilitation
Exclusion Criteria:
- medical contraindications that preclude safe exercise participation17
- unwillingness to comply with study protocols.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: In-person cardiac rehabilitation
Those randomized to in-person cardiac rehabilitation group
|
In-person CR consists of weekly group-based supervised exercise training at Women's College Hospital, supplemented with home-based exercise training, with the goal of reaching Canadian Physical Activity Guidelines of 150 minutes a week of moderate-intensity exercise per week.
Exercise prescriptions are individualized at baseline by the cardiac rehabilitation team.
Both study arms get have the opportunity to attend weekly synchronous virtual group video education sessions for the duration of the 12-week cardiac rehab program with the focus on self-management education and support.
|
Experimental: Virtual cardiac rehabilitation
Those randomized to the virtual, home-based rehabilitation group
|
Virtual CR consists of once-weekly telephone or video conferencing-based follow-ups (according to participant preference and access to internet/smart device) by one of the cardiac rehab providers.
Similar to the in-person program, the virtual program also encourages participants to set goals to achieve 150 minutes a week of moderate-intensity exercise.
The exercise prescription is individualized to each participant's ability and can vary in number of sessions per week and duration of each exercise session, as per the cardiac rehab provider's discretion.
Unlike the in-person program, all these sessions are completed at home in an unsupervised manner.
Both study arms get have the opportunity to attend weekly synchronous virtual group video education sessions for the duration of the 12-week cardiac rehab program with the focus on self-management education and support.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recruitment rate
Time Frame: 1 week after study completion
|
Defined as number of patients who agree to participate relative to the number of patients approached.
|
1 week after study completion
|
Intervention safety
Time Frame: 1 week post-intervention
|
Data on all intervention-related adverse events (as defined by the Common Terminology Criteria for Adverse Events [CTCAE]) will be collected and reported according to CTCAE-defined categories.
Non-trial related adverse events during the intervention period will also be recorded given that they may significantly impact participation.
|
1 week post-intervention
|
Intervention adherence
Time Frame: 1 week post-intervention
|
Exercise adherence will be collected as relative dose intensity (RDI; exercise dose performed in each session relative to prescribed exercise dose).
|
1 week post-intervention
|
Participant satisfaction
Time Frame: 1 week post-intervention
|
Satisfaction with the intervention and participant experiences will be collected via an investigator-created survey.
|
1 week post-intervention
|
Study retention
Time Frame: 1 week post-intervention
|
Retention will be assessed by measuring attrition throughout the intervention period.
|
1 week post-intervention
|
Reasons for drop-out
Time Frame: 1 week post-intervention
|
Reasons for dropout and/or non-compliance to assessment protocols will also be collected.
|
1 week post-intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Estimated aerobic fitness
Time Frame: 2 weeks before starting cardiac rehabilitation and 1 week after completing cardiac rehabilitation
|
Estimated peak aerobic fitness using a prediction equation and symptom-limited stress test, using either the Bruce or modified Bruce protocol completed prior to the first cardiac rehab exercise session and at program completion.
|
2 weeks before starting cardiac rehabilitation and 1 week after completing cardiac rehabilitation
|
Left ventricular ejection fraction (LVEF)
Time Frame: 2 weeks before starting cardiac rehabilitation, 1 week after completing cardiac rehabilitation, and 6 months after completing cardiac rehabilitation
|
Volumetric determination of LVEF assessed via electrocardiography in accordance with practice guidelines.
|
2 weeks before starting cardiac rehabilitation, 1 week after completing cardiac rehabilitation, and 6 months after completing cardiac rehabilitation
|
Global longitudinal strain (GLS)
Time Frame: 2 weeks before starting cardiac rehabilitation, 1 week after completing cardiac rehabilitation, and 6 months after completing cardiac rehabilitation
|
Determination of GLS via strain analysis assessed using electrocardiography
|
2 weeks before starting cardiac rehabilitation, 1 week after completing cardiac rehabilitation, and 6 months after completing cardiac rehabilitation
|
E/A ratio
Time Frame: 2 weeks before starting cardiac rehabilitation, 1 week after completing cardiac rehabilitation, and 6 months after completing cardiac rehabilitation
|
Measure of diastolic dysfunction assessed via electrocardiography in accordance with practice guidelines.
|
2 weeks before starting cardiac rehabilitation, 1 week after completing cardiac rehabilitation, and 6 months after completing cardiac rehabilitation
|
Duke Activity Status Index
Time Frame: 2 weeks before starting cardiac rehabilitation, 1 week after completing cardiac rehabilitation, and 6 months after completing cardiac rehabilitation
|
Self-reported measure of physical activity
|
2 weeks before starting cardiac rehabilitation, 1 week after completing cardiac rehabilitation, and 6 months after completing cardiac rehabilitation
|
Godin Leisure Time Exercise Questionnaire
Time Frame: 2 weeks before starting cardiac rehabilitation, 1 week after completing cardiac rehabilitation, and 6 months after completing cardiac rehabilitation
|
Self-reported measure of physical activity
|
2 weeks before starting cardiac rehabilitation, 1 week after completing cardiac rehabilitation, and 6 months after completing cardiac rehabilitation
|
Beck Depression Inventory
Time Frame: 2 weeks before starting cardiac rehabilitation, 1 week after completing cardiac rehabilitation, and 6 months after completing cardiac rehabilitation
|
Self-reported assessment of depression
|
2 weeks before starting cardiac rehabilitation, 1 week after completing cardiac rehabilitation, and 6 months after completing cardiac rehabilitation
|
Short-form survey (SF-36)
Time Frame: 2 weeks before starting cardiac rehabilitation, 1 week after completing cardiac rehabilitation, and 6 months after completing cardiac rehabilitation
|
Self-reported measure of quality of life
|
2 weeks before starting cardiac rehabilitation, 1 week after completing cardiac rehabilitation, and 6 months after completing cardiac rehabilitation
|
Work Limitations Questionnaire
Time Frame: 2 weeks before starting cardiac rehabilitation, 1 week after completing cardiac rehabilitation, and 6 months after completing cardiac rehabilitation
|
Self-reported assessment of degree to which individual's condition affects ability to return to work
|
2 weeks before starting cardiac rehabilitation, 1 week after completing cardiac rehabilitation, and 6 months after completing cardiac rehabilitation
|
Automated Self-Administered Dietary Assessment Tool (ASA24)
Time Frame: 2 weeks before starting cardiac rehabilitation, 1 week after completing cardiac rehabilitation, and 6 months after completing cardiac rehabilitation
|
Self-reported measure assessing individual's diet
|
2 weeks before starting cardiac rehabilitation, 1 week after completing cardiac rehabilitation, and 6 months after completing cardiac rehabilitation
|
Objective assessment of physical activity levels
Time Frame: 1 week after completing cardiac rehabilitation
|
Participants will be provided Fitbits for the duration of their participation in cardiac rehabilitation
|
1 week after completing cardiac rehabilitation
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Husam Abdel-Qadir, MD-PhD, Women's College Hospital
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2022-0088-E
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Diseases
-
Medical College of WisconsinRecruitingCardiovascular Diseases | Cardiovascular Risk Factor | Cardiovascular HealthUnited States
-
Hospital Mutua de TerrassaCompleted
-
Oregon Health and Science UniversityCompletedCardiovascular Disease | Cardiovascular Risk FactorsUnited States
-
Women's College HospitalUniversity Health Network, Toronto; Sunnybrook Health Sciences Centre; Brigham... and other collaboratorsUnknownCARDIOVASCULAR DISEASESCanada, United States
-
Groupe Hospitalier Paris Saint JosephTerminatedCARDIOVASCULAR DISEASESFrance
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
VA Office of Research and DevelopmentNot yet recruitingCardiovascular DiseaseUnited States
-
Baptist Health South FloridaUniversity of California, Los Angeles; Quest Diagnostics-Nichols InsituteActive, not recruitingCardiovascular DiseaseUnited States
-
Laval UniversityActive, not recruitingCardiovascular DiseaseCanada
-
Penn State UniversityCalifornia Healthcare InstituteCompleted
Clinical Trials on In-person supervised cardiac rehabilitation
-
University of California, San FranciscoPatient-Centered Outcomes Research Institute; Johns Hopkins University; Mayo... and other collaboratorsRecruitingMyocardial Infarction | Coronary Artery Disease | Heart Valve Diseases | Angina, Stable | Heart Failure, Systolic | Heart TransplantUnited States
-
Landseed HospitalNational Central University, Taiwan; Antai Medical Care Corperation Antai Tian-Sheng... and other collaboratorsCompletedPost-Acute-Stroke Rehabilitation
-
Wake Forest University Health SciencesRecruitingCardiac AmyloidosisUnited States
-
NYU Langone HealthCompleted
-
NYU Langone HealthCompleted
-
University Health Network, TorontoRecruitingAdvanced Breast Cancer | Advanced Colorectal Cancer | Cancer RehabilitationCanada
-
University of PennsylvaniaIndependence Blue Cross; CardaHealthActive, not recruitingHeart FailureUnited States
-
Federal University of PelotasRecruitingKnee OsteoarthritisBrazil
-
Centre Hospitalier Universitaire de Saint EtienneMinistry of Health, FranceRecruitingPulmonary Arterial HypertensionFrance